Coya Therapeutics, Inc. cotiza a 4.47 USD y tiene una capitalización bursátil de $105M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | — | $-0.32 | $-0.34 |
| Estimado | $-0.35 | $-0.36 | $-0.39 | $-0.30 |
| Sorpresa | — | — | +17.9% | -13.3% |
| Métrica | COYA | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -283.9% | -38.6% | -245.3% |
| Net Margin | -267.1% | -33.6% | -233.6% |
| FCF Margin | — | -13.9% | — |
| ROE | -49.3% | -40.4% | -8.9% |
| ROA | -42.5% | -32.0% | -10.5% |
| Current Ratio | 8.50 | 2.84 | +5.66 |
| Debt / Equity | — | 0.28 | — |